Creo Medical Group (LON:CREO) Reaches New 52-Week Low – Time to Sell?

Creo Medical Group PLC (LON:CREO)’s stock price reached a new 52-week low during trading on Monday . The company traded as low as GBX 14.25 ($0.18) and last traded at GBX 14.50 ($0.18), with a volume of 364450 shares traded. The stock had previously closed at GBX 14.55 ($0.19).

Creo Medical Group Stock Down 0.3 %

The company has a debt-to-equity ratio of 29.96, a current ratio of 3.24 and a quick ratio of 2.19. The business has a 50-day moving average of GBX 19.10 and a 200 day moving average of GBX 27.19. The company has a market capitalization of £52.46 million, a PE ratio of -241.67 and a beta of 0.86.

Insider Buying and Selling at Creo Medical Group

In other Creo Medical Group news, insider Kevin Crofton bought 2,916,666 shares of the business’s stock in a transaction dated Monday, October 21st. The shares were purchased at an average price of GBX 24 ($0.31) per share, with a total value of £699,999.84 ($892,060.46). Also, insider Richard John Rees acquired 98,000 shares of the company’s stock in a transaction that occurred on Thursday, October 24th. The stock was purchased at an average cost of GBX 20 ($0.25) per share, for a total transaction of £19,600 ($24,977.70). Company insiders own 22.43% of the company’s stock.

Creo Medical Group Company Profile

Creo Medical Group PLC, through its subsidiaries, researches, develops, manufactures, and sells medical devices and instruments in the United Kingdom. It is developing CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with flexible, accurate, and highly controllable devices delivered through a flexible endoscope.